These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18520343)

  • 1. A review of drug patch testing and implications for HIV clinicians.
    Shear NH; Milpied B; Bruynzeel DP; Phillips EJ
    AIDS; 2008 May; 22(9):999-1007. PubMed ID: 18520343
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
    Prasertvit P; Chareonyingwattana A; Wattanakrai P
    Contact Dermatitis; 2017 Dec; 77(6):379-384. PubMed ID: 28782122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity.
    Schnyder B; Adam J; Rauch A; Thurnheer MC; Pichler WJ
    J Allergy Clin Immunol; 2013 Sep; 132(3):756-758. PubMed ID: 23706613
    [No Abstract]   [Full Text] [Related]  

  • 5. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 6. Exuberant Positive Patch Test to Abacavir in a Patient with the HLA-B*5701 Haplotype.
    Micozzi S; Rojas P; Rodriguez-Gamboa A; De Barrio M
    J Allergy Clin Immunol Pract; 2015; 3(6):965-7. PubMed ID: 26116952
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnosis and management of HIV drug hypersensitivity.
    Davis CM; Shearer WT
    J Allergy Clin Immunol; 2008 Apr; 121(4):826-832.e5. PubMed ID: 18190954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine toxicity.
    Taiwo BO
    Int J STD AIDS; 2006 Jun; 17(6):364-9; quiz 370. PubMed ID: 16734954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 11. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity to antiretroviral drugs.
    Sousa MJ; Cadinha S; Mota M; Teixeira T; Malheiro D; Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2018 Nov; 50(6):277-280. PubMed ID: 29384113
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypersensitivity reactions to drugs in HIV-infected patients. Allergic evaluation and desensitization.
    Moreno-Ancillo A; López-Serrano MC
    Clin Exp Allergy; 1998 Sep; 28 Suppl 4():57-60. PubMed ID: 9761034
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system.
    Vilar FJ; Naisbitt DJ; Park BK; Pirmohamed M
    J HIV Ther; 2003 May; 8(2):42-7. PubMed ID: 12838164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety in routine clinical practice. Hypersensitivity can be managed].
    MMW Fortschr Med; 2000; 142(3 Suppl):22-3. PubMed ID: 10893956
    [No Abstract]   [Full Text] [Related]  

  • 20. Late reaction to oral nystatin: the importance of patch testing.
    de la Borbolla JM; Goikoetxea MJ; Cabrera-Freitag P; Gastaminza G
    J Investig Allergol Clin Immunol; 2009; 19(4):321-2. PubMed ID: 19639730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.